Secretory phospholipase A2 mediates progression of acute liver injury in the absence of sufficient cyclooxygenase-2

Toxicology and Applied Pharmacology

Volumn 228, Issue 2, 2008, Pages 225-238

  Bhave, Vishakha S ^a   Donthamsetty, Shashikiran ^a   Latendresse, John R ^b   Muskhelishvili, Levan ^b   Mehendale, Harihara M ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b Pathology Associates International   (United States)

Author keywords

Arachidonic acid; Carbon tetrachloride; Cycloxygenase 2; Necrotic debris; Prostaglandin E2; Secretory phospholipase A2

Indexed keywords

ALANINE AMINOTRANSFERASE; ARACHIDONIC ACID; CARBON TETRACHLORIDE; CYCLOOXYGENASE 2; PHOSPHOLIPASE A2; PHOSPHOLIPID DERIVATIVE; PROSTAGLANDIN E2; CYCLOOXYGENASE 1; LACTATE DEHYDROGENASE; SECRETORY PHOSPHOLIPASE A2;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DESTRUCTION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME RELEASE; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LETHALITY; LIVER CELL MEMBRANE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALE; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; INJURY; INTOXICATION; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; LIVER CELL; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; SURVIVAL RATE; TIME;

RATTUS;

ACUTE DISEASE; ALANINE TRANSAMINASE; ANIMALS; CARBON TETRACHLORIDE; CARBON TETRACHLORIDE POISONING; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; L-LACTATE DEHYDROGENASE; LIVER; MALE; MODELS, BIOLOGICAL; PHOSPHOLIPASES A2, SECRETORY; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TIME FACTORS;

EID: 41549131209     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.12.023     Document Type: Article

References (63)

1. 2 in liver of carbon tetrachloride-treated rat. J. Health Sci. 46 (2000) 275-281
2. 2. Biol. Pharm. Bull 27 (2004) 1174-1178
3. 2 and peroxisome proliferator-activated receptor alpha activation. J. Biol. Chem. 278 (2003) 29799-29812
4. Beraza N., Marques J.M., Martinez-Anso E., Iniguez M., Prieto J., and Bustos M. Interplay among cardiotrophin-1, prostaglandins, and vascular endothelial growth factor in rat liver regeneration. Hepatology 41 (2005) 460-469
5. 2. Br. J. Pharmacol. 134 (2001) 197-205
6. Bessems J.G., and Vermeulen N.P. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31 (2001) 55-138
7. 2 by human annexin V. Biochem. J. 329 Pt 2 (1998) 369-372
8. 2. Biochim. Biophys. Acta 1391 (1998) 367-376
9. Casado M., Callejas N.A., Rodrigo J., Zhao X., Dey S.K., Bosca L., and Martin-Sanz P. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy. FASEB J. 15 (2001) 2016-2018
10. Chakraborti S. Phospholipase A(2) isoforms: a perspective. Cell Signal 15 (2003) 637-665
11. 2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266 (1991) 2647-2651
12. Cummings B.S., McHowat J., and Schnellmann R.G. Phospholipase A(2)s in cell injury and death. J. Pharmacol. Exp. Ther 294 (2000) 793-799
13. 2 inhibitor. J. Neurotrauma. 21 (2004) 1683-1691
14. Demeure C.E., Yang L.P., Desjardins C., Raynauld P., and Delespesse G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur. J. Immunol. 27 (1997) 3526-3531
15. Fernandez-Martinez A., Callejas N.A., Casado M., Bosca L., and Martin-Sanz P. Thioacetamide-induced liver regeneration involves the expression of cyclooxygenase 2 and nitric oxide synthase 2 in hepatocytes. J. Hepatol. 40 (2004) 963-970
16. Guengerich F.P. Life and times in biochemical toxicology. Int. J. Toxicol. 24 (2005) 5-21
17. Guengerich F.P., and Liebler D.C. Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol. 14 (1985) 259-307
18. Holzbach R.T. Drug-induced liver disease. Prim Care 8 (1981) 231-250
19. Hortelano S., Zeini M., Casado M., Martin-Sanz P., and Bosca L. Animal models for the study of liver regeneration: role of nitric oxide and prostaglandins. Front Biosci. 12 (2007) 13-21
20. 2 in mononuclear phagocytic cells in rat spleen and liver. Eur. J. Biochem. 197 (1991) 323-329
21. Ishikawa Y., Komiyama K., Masuda S., Murakami M., Akasaka Y., Ito K., Akishima-Fukasawa Y., Kimura M., Fujimoto A., Kudo I., and Ishii T. Expression of type V secretory phospholipase A in myocardial remodelling after infarction. Histopathology 47 (2005) 257-267
22. 2 expression in human hepatocytes damaged by liver disease. J. Gastroenterol. Hepatol. 19 (2004) 1140-1149
23. 2. Arterioscler Thromb Vasc. Biol. 19 (1999) 1284-1290
24. 2 by sphingomyelin and annexin VI. Biochem J. 326 Pt 1 (1997) 227-233
25. 2. J. Biol. Chem. 264 (1989) 5768-5775
26. 2. Biochim. Biophys. Acta 1170 (1993) 217-231
27. 2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J. Biol. Chem. 273 (1998) 1733-1740
28. Lappas M., Permezel M., and Rice G.E. 15-Deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta 27 (2006) 1060-1072
29. Lee K.M., Kang B.S., Lee H.L., Son S.J., Hwang S.H., Kim D.S., Park J.S., and Cho H.J. Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur. J. Neurosci. 19 (2004) 3375-3381
30. Lee K.W., Kim M.S., Kang N.J., Kim D.H., Surh Y.J., Lee H.J., and Moon A. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells. Int J. Cancer 119 (2006) 1767-1775
31. Lesca P. Metabolic activation and toxicology - some models of chemical protection against drug toxicity. Toxicol. Eur. Res. 3 (1981) 161-166
32. Limaye P.B., Apte U.M., Shankar K., Bucci T.J., Warbritton A., and Mehendale H.M. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol. Appl. Pharmacol. 191 (2003) 211-226
33. Mehendale H.M. Toxicodynamics of low level toxicant interactions of biological significance: inhibition of tissue repair. Toxicology 105 (1995) 251-266
34. Mehendale H.M., and Limaye P.B. Calpain: a death protein that mediates progression of liver injury. Trends Pharmacol. Sci. 26 (2005) 232-236
35. 2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat 79 (2006) 1-33
36. 2. J. Biochem (Tokyo) 131 (2002) 285-292
37. 2. Biol. Pharm. Bull 27 (2004) 1158-1164
38. 2. Crit Rev. Immunol 17 (1997) 225-283
39. 2 associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation. J. Biol. Chem. 271 (1996) 30041-30051
40. 2. J. Biol. Chem. 273 (1998) 14411-14423
41. Napirei M., Basnakian A.G., Apostolov E.O., and Mannherz H.G. Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice. Hepatology 43 (2006) 297-305
42. 2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. J. Immunol. 160 (1998) 2974-2982
43. 2 in rat cultured astrocytes. Two distinct pathways of the gene expression. J. Biol. Chem. 266 (1991) 9956-9960
44. Oppenheimer-Marks N., Kavanaugh A.F., and Lipsky P.E. Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2. J. Immunol. 152 (1994) 5703-5713
45. Parke D.V., and Sapota A. Chemical toxicity and reactive oxygen species. Int. J. Occup Med. Environ. Health 9 (1996) 331-340
46. Piraino G., Cook J.A., O'Connor M., Hake P.W., Burroughs T.J., Teti D., and Zingarelli B. Synergistic effect of peroxisome proliferator activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages. Shock 26 (2006) 146-153
47. 4 hepatotoxicity: a novel dose-response. Toxicology 118 (1997) 181-193
48. Reilly T.P., Brady J.N., Marchick M.R., Bourdi M., George J.W., Radonovich M.F., Pise-Masison C.A., and Pohl L.R. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem. Res. Toxicol. 14 (2001) 1620-1628
49. Rincon-Sanchez A.R., Covarrubias A., Rivas-Estilla A.M., Pedraza-Chaverri J., Cruz C., Islas-Carbajal M.C., Panduro A., Estanes A., and Armendariz-Borunda J. PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. Exp. Toxicol. Pathol. 56 (2005) 291-303
50. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol. 13 (1976) 29-83
51. 2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem 264 (1989) 5335-5338
52. 2S. J. Biol. Chem. 274 (1999) 12263-12268
53. Soni M.G., Mangipudy R.S., Mumtaz M.M., and Mehendale H.M. Tissue repair response as a function of dose during trichloroethylene hepatotoxicity. Toxicol Sci. 42 (1998) 158-165
54. 2 prevent renal injury due to ischemia and reperfusion in rats. FEBS Lett 440 (1998) 377-381
55. Tessier C., Hichami A., and Khan N.A. Implication of three isoforms of PLA(2) in human T-cell proliferation. FEBS Lett. 520 (2002) 111-116
56. Titos E., Claria J., Planaguma A., Lopez-Parra M., Gonzalez-Periz A., Gaya J., Miquel R., Arroyo V., and Rodes J. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J. Leukoc. Biol. 78 (2005) 871-878
57. Williams R.T. Detoxification Mechanisms (1959), New York, Wiley
58. Williams R.T. Nutrients in drug detoxification reactions. In: Hathcock J.N., and Coon J. (Eds). Nutrition and Drug Interrelations (1978), New York, Academic Press
59. Winstead M.V., Balsinde J., and Dennis E.A. Calcium-independent phospholipase A(2): structure and function. Biochim. Biophys. Acta 1488 (2000) 28-39
60. 2. A novel mechanism underlying arachidonic acid mobilization. J. Biol. Chem. 272 (1997) 1522-1526
61. 2 protects rats from TNBS-induced colitis. Int Immunopharmacol. 5 (2005) 883-892
62. Yu J., Ip E., Dela Pena A., Hou J.Y., Sesha J., Pera N., Hall P., Kirsch R., Leclercq I., and Farrell G.C. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43 (2006) 826-836
63. Zeini M., Hortelano S., Traves P.G., Martin-Sanz P., and Bosca L. Simultaneous abrogation of NOS-2 and COX-2 activities is lethal in partially hepatectomised mice. J. Hepatol. 40 (2004) 926-933